VivoSeq
0

Pipeline Programs

2

Active Trials

0

Companies Involved

OIC is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

27/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

15

clinical trials

Completed8 · 53%
Withdrawn2 · 13%
Terminated2 · 13%
Unknown status1 · 7%
Active, not recruiting1 · 7%
Not yet recruiting1 · 7%

Trial Activity

15 trials

CHemical OptImization of Cerebral Embolectomy 2 (CHOICE 2).
Active, not recruiting·HHospital Clinic of Barcelona·Phase 3·NCT05797792·440 enrolled
Valproic Acid in Treating Cyanotic Breath Holding Spells
Completed··Phase 1·NCT04482764·150 enrolled
A Better Choice for Patients Undergoing Endovascular Coil Embolization
Completed··Phase 4·NCT01722409·64 enrolled
RA-2 13-cis Retinoic Acid (Isotretinoin)
Completed·UUniversity of Washington·Phase 2·NCT02061384·20 enrolled
Safety and Efficiency Study of Valproic Acid In HAM/TSP
Terminated··N/A·NCT00519181·19 enrolled
HEROIC (Heparin Requirement in Counterpulsation)
Terminated·CCorewell Health East·Phase 2·NCT00445211·46 enrolled
Faces: Choices Study
Withdrawn·UUniversity of Florida·Phase 2/3·NCT02409862

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)